Artiva Biotherapeutics, Inc.
NASDAQ:ARTVBiotechnology
-$0.34 today
- Market cap
- $189.33M
- Beta
- 2.40
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$3.53
Volume 0.77M
Average 0.48M
Returns on capital
Artiva Biotherapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-76.3%
avg 16.5%
ROIC
-74.9%
avg -43.7%
ROA
-64.0%
avg -38.0%
Analysis
ROA is currently the strongest return metric at -64.0% versus its period average of -38.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Fred Aslan | CEO, Principal Financial & Accounting Officer and Director | USD 1.22M | 51 | 1.46M | 5.90% |
Jennifer Kinsbruner Bush | Chief Operating Officer | USD 839.21K | 51 | — | — |
Christopher Horan | Chief Technical Operations Officer | USD 777.62K | 59 | 302.32K | 1.22% |
Peter Flynn | Co-Founder & Strategic Advisor | USD 499.37K | 52 | — | — |
Gines Diego Miralles | President and Head of Research & Development | USD 55K | 64 | 122.50K | 0.50% |
David Moriarty | Senior Vice President of Clinical Operations | — | — | — | — |
Heather Raymon | Senior Vice President of Research & Early Development | — | 61 | 148.23K | 0.60% |
Nicholas Veomett | Vice President of Corporate Development | — | — | — | — |
Andrew Cronauer | VP, General Counsel & Corporate Secretary | — | — | — | — |
Benjamin Dewees | Senior Vice President of Regulatory Affairs | — | — | — | — |
Feng Xu | Senior Vice President of Biometrics | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 2, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
23
$109.18M
Sells
22
$2.84M
Net Transaction Value
+$106.34M
Net buying
Most Active
RA CAPITAL MANAGEMENT, L.P.
21 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 2, 26Nov 2, 2026 | Horan Christopher Direct | Sell | $43.6K$43,579.61 |
| Nov 2, 26Nov 2, 2026 | Bush Jennifer Direct | Sell | $35.3K$35,284.30 |
| Nov 2, 26Nov 2, 2026 | Banerjee Subhashis Direct | Sell | $4.6K$4,641.02 |
| Nov 2, 26Nov 2, 2026 | Aslan Fred Direct | Sell | $260K$259,972.44 |
| Oct 6, 26Oct 6, 2026 | Aslan Fred Direct | Sell | $168.9K$168,879.64 |
| Oct 5, 26Oct 5, 2026 | Horan Christopher Direct | Sell | $70.7K$70,696.65 |
| Oct 5, 26Oct 5, 2026 | Bush Jennifer Direct | Sell | $57.2K$57,227.36 |
| Oct 5, 26Oct 5, 2026 | Banerjee Subhashis Direct | Sell | $7.5K$7,514.08 |
| Oct 5, 26Oct 5, 2026 | Aslan Fred Direct | Sell | $421.8K$421,827.89 |
| Sep 8, 26Sep 8, 2026 | Aslan Fred Direct | Sell | $255.7K$255,746.28 |
1–10 of 45
Summary
Insiders reported 23 buys worth $109.18M and 22 sells worth $2.84M over the last 12 months. That adds up to net buying of $106.34M. RA CAPITAL MANAGEMENT, L.P. was the most active insider with 21 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Artiva Biotherapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about ARTV's management, answered from reported figures.
Who manages ARTV?
Artiva Biotherapeutics, Inc. (ARTV) lists 11 active executives. The top listed executive is David Moriarty, Senior Vice President of Clinical Operations.
Are ARTV insiders buying or selling?
Recent insider activity shows net buying of $2.17T.
Continue the stock analysis
Jump to another research area for this company.